The Review of
DIABETIC
STUDIES

Metformin and Cancer

Natalia G. Vallianou[1], Angelos Evangelopoulos[2], and Christos Kazazis[3]

[1] First Department of Internal Medicine, Evangelismos General Hospital, 10676 Athens, Greece. [2] Roche Diagnostics Hellas, 15125, Maroussi, Athens, Greece. [3] Honorary Lecturer, School of Medicine, University of Leicester, University Rd, Leicester, LE1 9HN, UK. Address correspondence to: Natalia G. Vallianou, MD, PhD, First Department of Internal Medicine, Evangelismos General Hospital, 45-49 Ipsilantou str, 10676 Athens, Greece, e-mail: natalia.vallianou@hotmail.com

■ Abstract

Metformin is well-known as an anti-diabetic drug, but it seems to possess anti-cancerous properties as well. Adenosine monophosphate-activated protein kinase (AMPK) is a highly conserved regulator of the cellular response to the presence of low energy in all eukaryotic cells. It is considered a key sensor of the balance of cellular ATP and AMP concentrations. LKB1 serine/threonine kinase is a divergent yet evolutionarily well-conserved kinase, biochemically sufficient to activate AMPK *in vitro* and genetically required for AMPK activation. Because of this potent connection to AMPK, LKB1 may act as a central regulator of metabolism *in vivo*. Once activated, AMP kinase phosphorylates the transcriptional activator TorC2, thereby blocking its nuclear translocation and inhibiting the expression of genes involved in gluconeogenesis. Data suggest that LKB1/AMPK signaling plays a role in protection from apoptosis, specifically in response to agents that increase the cellular AMP/ATP ratio. Active AMPK signaling offers a protective effect by providing the cell with time to reverse the aberrantly high ratio of AMP/ATP. If unable to reverse this ratio, the cell will eventually undergo cell death. These observations offer the provocative suggestion of a potential therapeutic window in which LKB1-deficient tumor cells may be acutely sensitive to AMP analogues or sensitized to cell death by other stimuli when treated in combination with agents that increase the AMP/ATP ratio. LKB1 therefore is a classical tumor suppressor. AMPK is a direct LKB1 substrate. A consequence of AMPK activation by LKB1 is the inhibition of the mammalian target of rapamycin (mTOR) C1 pathway. Metformin's anti-cancerous properties have been demonstrated in various cancer cells *in vitro*, such as lung, pancreatic, colon, ovarian, breast, prostate, renal cancer cells, melanoma, and even in acute lymphoblastic leukemia cells. To test metformin's action *in vivo*, mice were implanted with transformed mammary epithelial cells and treated with three cycles of metformin and with the anthracycline doxorubicin. When combined with doxorubicin, metformin wiped out tumors and prevented recurrence. Metformin alone had no effect, and doxorubicin as a single agent initially shrank tumors, but they regrew later. Virtually no cancer stem cells were recovered immediately after treatment and the complete response was sustained for nearly two months. Further studies are needed to assess the anti-cancerous potentials of metformin *in vivo*. This article reviews the current knowledge on the actions of LKB1/AMPK and the effectiveness of metformin in cancer, specifically in diabetes patients.

Keywords: AMPK · LKB1 · metformin · doxorubicin

Introduction

It is well-established that colorectal cancer incidence is increased among patients with type 2 diabetes mellitus [1-4]. Certain types of cancers are more common in people with diabetes than in those without. Diabetes is also associated with reduced survival after cancer [5-8]. Therefore, it is important to address the topic of cancer and in diabetes in future research.

Adenosine-monophosphate-activated protein kinase (AMPK)

Adenosine monophosphate-activated protein kinase (AMPK) is a highly conserved regulator of the cellular response to low energy expressed in all eukaryotic cells. AMPK is activated when intracellular adenosine triphosphate (ATP) concentrations decrease and AMP concentrations increase [9]. It is considered a key sensor for the balance of cellu-

lar ATP and AMP concentrations. AMPK is activated by:

1. Stimuli that induce stress including oxidative damage, osmotic shock, hypoxia, and deprivation of glucose or other nutrients.
2. Mitochondrial poisons.
3. Physiological stimuli including exercise, muscle contraction, and hormones such as leptin and adiponectin [10].

In mammals, AMPK has a critical role in metabolic processes, including glucose uptake and fatty acid oxidation in muscle, fatty acid synthesis and gluconeogenesis in the liver, and the regulation of food intake centrally at the hypothalamus level [11-13].

AMPK exists as a heterotrimer complex, composed of the catalytic kinase α subunit and two associated regulatory subunits, β and γ [11]. Upon energy stress, AMP directly binds to tandem repeats of crystathionine-β synthase (CBS) domains in the AMPK γ subunit, causing a conformation change that exposes the activation loop in the α subunit, allowing it to be phosphorylated by an upstream kinase [10]. The sequence flanking the activation loop threonine (Thr172 in human AMPKα1) is conserved across species and its phosphorylation is absolutely required for AMPK activation. Phosphorylation of a single invariant threonine residue in the activation loop of the catalytic subunit (Thr172 in human AMPKα1) has been shown to be required to activate all known AMPK homologues [12]. A number of laboratories have reported biochemical purification of a kinase activity, AMPK kinase (AMPKK), which is capable of phosphorylating Thr172 [14-17]. Calcium calmodulin-dependent protein kinase kinase (CAMKK) has been demonstrated to serve as a surrogate AMPKK *in vitro*, but not *in vivo* [18].

The LKB1 serine/threonine kinase is a divergent yet evolutionarily well conserved kinase that most closely resembles CAMKK in its catalytic domain. Threonine kinase LKB1 is biochemically sufficient to activate AMPK *in vitro* and is genetically required for AMPK activation by energy stress in a number of mammalian cell lines [19-20]. Because of this potent connection to AMPK, LKB1 may act as a central regulator of metabolism *in vivo* [21-26]. Once activated, AMP kinase phosphorylates the transcriptional activator TorC2, thereby blocking its nuclear translocation and inhibiting the expression of genes involved in gluconeogenesis (**Figure 1**) [23].

Abbreviations:
AMP - adenosine monophosphate
AMPK - adenosine-monophosphate-activated protein kinase
ATP - adenosine triphosphate
CAMKK - calmodulin-dependent protein kinase kinase
CBS - crystathionine-β synthase
IGF-IR - insulin-like growth factor insulin receptor
IR - insulin receptor
LKB1 - liver kinase B1 (a threonine/serine kinase)
MAPK - mitogen-activated protein kinase
mTOR - mammalian target of rapamycin
Thr172 - threonine 172
TORC2 - target of rapamycin complex 2

LKB1/AMPK and diabetes

The ability of metformin to lower glucose and insulin levels by inhibiting the expression of genes involved in gluconeogenesis is a satisfactory explanation of its therapeutic effect in diabetes [9]. Mice deficient in hepatic LKB1 develop hyperglycemia and are resistant to the glucose-lowering effects of metformin [21].

There is genetic and biochemical evidence that LKB1 is a critical regulator of AMPK *in vivo*. As such, LKB1 may play an unexpected role in multiple organ systems that mediate the diverse effects of AMPK on mammalian physiology. Importantly, AMPK has been shown to be a critical mediator of glucose uptake in skeletal muscle in mice. The kinase activity of AMPK is stimulated by two major anti-diabetic drugs, metformin and rosiglitazone [27-28]. Therefore, the identification of LKB1 as a major activator of AMPK *in vivo* may offer potential avenues to boost AMPK activity for the treatment of diabetes.

LKB1/AMPK and apoptosis

Data suggest that LKB1/AMPK signaling plays a role in protection from apoptosis, specifically in response to agents that increase the cellular AMP/ATP ratio. Active AMPK signaling induces a protective effect by providing the cell with time to reverse the aberrantly high ratio of AMP/ATP. If unable to reverse this ratio, the cell will eventually undergo cell death. These results offer the provocative suggestion of a potential therapeutic window in which LKB1-deficient tumor cells may be acutely sensitive to AMP analogues or sensitized to cell death by other stimuli when treated in combination with agents that increase the AMP/ATP ratio.

AMP kinase is activated by the product of the Peutz-Jegher tumor suppressor gene LKB1 [29].

Figure 1. Action of metformin in diabetes. Metformin activates adenosine-monophosphate-activated protein kinase (AMPK), which phosphorylates the target of rapamycin complex 2 (TORC2), thereby blocking its nuclear translocation and transcription of the genes involved in gluconeogenesis. Liver kinase B1 (LKB1) is essential for the activation of AMPK. Positive AMPK signals prevent the mitogenic activity of mammalian target of rapamycin (mTOR) C1 pathway.

Peutz-Jeghers syndrome patients develop numerous benign tumors in the gastrointestinal tract and have a 20-fold increased risk of developing malignant tumors at other sites. Mutations in the LKB1 gene are also seen in some sporadic cancers, especially lung adenocarcinoma [30-31]. Therefore, LKB1 is a classical tumor suppressor [32]. AMPK is a direct LKB1 substrate. A consequence of AMPK activation by LKB1 is the inhibition of the mammalian target of rapamycin (mTOR) C1 pathway through phosphorylation of tuberous sclerosis 2 or hamartin and raptor [33-34].

As mentioned above, loss of LKB1 function is a frequent finding in lung adenocarcinoma and squamous cell carcinomas [20]. Interestingly, the anti-diabetic drug rosiglitazone is known to stimu-late AMPK signaling through alterations in the intracellular AMP/ATP ratio, suggesting that rosiglitazone may be useful in the treatment of LKB1-deficient tumors as well [28]. The observation that altered AMP/ATP ratios result in cell death in the absence of AMPK signaling indicates that other cellular proteins that are regulated by AMP may contribute to the cell death observed.

LKB1 tumor suppression seems to be the major activating kinase for AMPK in the liver. As Shaw *et al.* suggested, minor roles for other kinases cannot be ruled out, but under all the conditions they have examined, the loss of LKB1 was mirrored by the loss of AMPK phosphorylation [26].

mTOR, insulin, and LKB1 pathways represent a fundamental eukaryotic network governing cell growth in response to environmental nutrients; dysregulation of one of these pathways contributes to both diabetes and cancer [29-32].

Metformin and various cancer cells

The involvement of a tumor suppressor pathway as a target for metformin's action in glucose homeostasis prompted studies of possible effects in tumor cells and animal cancer models. *In vitro* studies have shown that metformin inhibits the proliferation of colorectal cancer cells [33]. *In vivo* studies have demonstrated that metformin delays tumor onset in mouse models for p53 mutant colon cancer [34]. Another animal model of colon cancer has indicated that metformin inhibits colon carcinoma growth stimulated by a high-energy diet [35]. Two animal models of colorectal aberrant crypt foci showed that metformin significantly suppresses colonic epithelial proliferation by inhibiting the mTOR pathway [36-39]. This pathway has recently been found to be involved in T cell acute lymphoblastic leukemia [40]. Indeed, metformin has been shown to have therapeutic effects in T cells of acute lymphoblastic leukemia *in vitro* [41].

Metformin exerts *in vitro* inhibition of the proliferation of prostate, ovarian, and breast cancer cells [39]. This inhibitory effect is seen, however, at concentrations that are at least 10-fold higher than the peak plasma concentration attained with typical dosing in diabetics [42]. Even though most laboratory studies have been using doses that are much lower than the typical anti-diabetic dose of metformin used *in vivo*, there are emerging studies which show that even lower doses of metformin could have substantial anti-cancerous effects. For example, the proliferation of CD133[+], but not CD24[+]CD44[+]ESA[+] cells, which are considered pan-

creatic cancer stem cells, was inhibited by low doses of metformin [43]. Recently, it has been shown that the conventional anti-diabetic concentrations of metformin caused death in cancer cells and were preferentially cytotoxic to cancer stem cells related to non-cancer stem cells [44]. Also, to demonstrate the action of potential anti-cancerous properties of metformin *in vivo,* mice with transformed mammary epithelial cells were given three cycles of metformin and one cycle of doxorubicin, resulting in shrinking tumor cells and the prevention of recurrence. Mouse xenograft models demonstrate *in vivo* anti-tumor effects of metformin against pancreatic, prostate, and *p53* mutant colon cancers [33, 45-47].

AMPK is critically linked to the phosphatidylinositol-3 kinase/AKT/mTOR signaling pathway, a vital cellular signaling cascade that is essential for cell growth in response to mitogenic stimuli or pathways activated by growth factor receptors [48]. AMPK activation directly inhibits phosphorylation and subsequent activation of the mTORC1 complex and is controlled partly by the upstream kinase AKT, whose activation decreases the AMP:ATP ratio [35, 49-51]. AKT also directly inhibits the activation of AMPK by phosphorylation of AMPK at Ser 485/491 [52-53]. Renal cell carcinoma is a highly aggressive genitourinary cancer for which the treatment options are limited [54]. This malignancy is characterized by overactivation of this AKT/mTOR signaling pathway [55]. Extensive work over the last few years has demonstrated the effectiveness of targeting the mTOR pathway for the treatment of renal cell carcinoma [56]. Temsirolimus, a known mTOR pathway inhibitor, has clinically significant activity in the treatment of renal cell carcinoma and is now an FDA-approved agent in the treatment of patients with renal cell carcinoma [57]. Studies have demonstrated that addition of metformin exerted suppressive effects on the tumorogenicity of renal cancer cells *in vitro.*

It has been suggested that inhibitory effects on the LKB1/AMPK axis in melanoma may constitute an important mechanism of tumorigenesis [58]. Studies using both melanoma cell lines harboring this BRAF mutation and melanoma cell lines without this mutation suggest that AMPL plays a role in the control of malignant melanoma cell growth. Taken together, the above-mentioned studies provide evidence for potent inhibitory effects of AMPK on malignant melanoma cell growth and survival and raise the potential of AMPK manipulation as a novel future approach for the treatment of malignant melanoma [59].

Metformin and breast cancer

The discovery that metformin selectively kills cancer stem cells adds further interest and may explain its antineoplastic properties. Hirsch *et al.* genetically manipulated human breast epithelial cells to enrich for stem cells and tested these together with three distinct breast tumor cell lines [60]. Using flow cytometry to track the effects of metformin, researchers found that the drug is selectively toxic to cancer stem cells. To test metformin's action *in vivo*, mice were implanted with transformed mammary epithelial cells and treated with three cycles of metformin and with the anthracycline doxorubicin. When combined with doxorubicin, metformin wiped out tumors and prevented recurrence. Metformin alone had no effect and doxorubicin as a single agent initially shrank tumors but they regrew later. Virtually no cancer stem cells were recovered immediately after treatment and the complete response was sustained for nearly two months [61]. Among patients with breast cancer, the metformin-treated subgroup has been related with better outcomes than patients not treated with metformin [62].

Further studies will delineate whether the AMP kinase pathway is important in cancer stem cells, and whether the synergistic effect of metformin and anthracyclines is generalized to other types of cancer and to its combination with other drugs [63].

Metformin and colorectal cancer

Type 2 diabetes has been associated with increased incidence of colorectal cancer [64]. Recently, a study has revealed a significant association between highly intensive use of metformin and lower mortality from colorectal cancer in diabetics with stage I-III colorectal cancer compared with non-diabetics with stage I-III colorectal cancer [65]. Also, metformin use has been related with decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer [66]. Overall survival has been found to be better among patients with colorectal cancer and type 2 diabetes taking metformin as part of their anti-diabetic medication compared with diabetic patients with colorectal cancer not taking metformin as part of their anti-diabetic regimen [67]. In Korean patients with colorectal cancer, the use of metformin has been associated with reduced risk of overall mortality, especially in patients with stage III colorectal cancer [68].

Figure 2. Insulin-binding and metabolic action of insulin. Insulin binds both to the insulin receptor (IR) and to insulin-like growth factor receptor 1 (IGF-1R). The binding of insulin to IGF-1R activates both phosphoinositol-3-kinase pathway (PI3K), which activates the metabolic pathway, and mitogen-activated-protein-kinase (MAPK), which promotes cell growth and cell proliferation. The binding of insulin to IR is responsible for the metabolic actions of insulin.

Metformin, cancer prevention, and mortality

As shown by Curie *et al.*, diabetic patients with type 2 diabetes taking metformin had a decreased risk of cancer compared with patients taking metformin plus sulfonylurea and patients on insulin treatment [69]. Metformin has been related with lower incidence of cancer among type 2 diabetes patients [70]. Many studies support the notion that the use of metformin results in lower incidence of cancer [71-75]. Lung, pancreatic, prostate, breast, ovarian, and hepatocellular cancer incidence has been found to be lower among patients receiving metformin [76-82]. Moreover, the mortal-

ity from cancer was lower in diabetes patients taking metformin as part of their anti-diabetic medication compared with those not taking metformin [83-86]. However, studies showing favorable effects of metformin on cancer are not always corroborated by large clinical trials. Larger studies are expected to investigate the possible antineoplastic effects of metformin more thoroughly [87-89].

Conclusions

Metformin exerts its anti-tumor effects mainly through the AMPK/LKB1/TORC1 signaling pathway, thereby causing apoptosis in cancerous cells [14, 21-23]. Another possible mechanism is amelioration of endogenous hyperinsulinemia by use of metformin therapy [90]. Insulin stimulates cellular proliferation, and multiple signaling pathways are activated after insulin receptors or insulin-like growth factor (IGF-I) receptors interact with their ligands [91-92].

Most cancer cells express insulin and IGF-I receptors. The A isoform of the insulin receptor is also commonly expressed, which may stimulate mitogenesis, even in cells deficient in IGF-I [93-94]. Metformin therapy decreases the levels of circulating insulin-like growth factors and insulin which, in turn, may reduce the risk of cancer (**Figure 2**).

Other possible mechanisms underlying the potential anti-tumor effect of metformin could be the antagonization of obesity and anti-inflammatory effects. Interleukin-6, plasminogen activator inhibitor-1, tumor necrosis factor-α, and monocyte chemoattractant are produced by adipose tissue and can enhance cancer cell proliferation, p-53 activation, downregulation of cyclin D1, and killing of cancer stem cells [95-98]. Further studies investigating potential mechanisms of the anti-cancerous properties of metformin are needed.

If metformin effectively helps cancer patients, it will finally join drugs such as thalidomide, retinoic acid, and arsenic, which have unique mechanisms of action and were first used elsewhere in medicine, but have also found their way into the field of anticancer drugs.

Disclosure: The authors declare no conflict of interests.

■ References

1. **Seow A, Yuan JM, KohWP, Lee HP, Yu MC.** Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. *J Natl Cancer Inst* 2006. 98:135-138.
2. **Yang YX, Hennessy S, Lewis JD.** Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus pa-

tients. *Gastroenterology* 2004. 127:1044-1050.
3. **Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D.** Diabetes and cancer: a consensus report. *Diabetes Care* 2010. 33:1674-1685.
4. **Li C, Balluz LS, Ford ES, Okoro CA, Tsai J, Zhao G.** Association between diagnosed diabetes and self-reported

cancer among U.S. adults: findings from the 2009 behavioral risk factor surveillance system. *Diabetes Care* 2011. 34:1365-1368.

5. **Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R.** Diabetes and cancer. *Endocr Relat Cancer* 2009. 16:1103-1123.

6. **Nicolucci A.** Epidemiological aspects of neoplasms in diabetes. *Acta Diabetol* 2010. 47:87-95.

7. **Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE.** The impact of diabetes on survival following breast cancer. *Breast Cancer Res Treat* 2008. 109:389-395.

8. **Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL.** Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. *JAMA* 2008. 300:2754-2764.

9. **Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE.** Role of AMP activated protein kinase in mechanism of metformin action. *J Clin Invest* 2001. 108:1167-1174.

10. **Hardie DG, Scott J W, Pan DA, Huson ER.** Management of cellular energy by the AMP-activated protein kinase system. *FEBS Lett* 2003. 546:1113-1120.

11. **Kahn BB, Alquier T, Carling D, Hardie DG.** AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metab* 2005. 1:15-25.

12. **Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferré P, Birnbaum MJ, Stuck BJ, Kahn BB.** AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. *Nature* 2004. 428:569-574.

13. **Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, Carlinq D, Small CJ.** AMP-activated protein kinase plays a role in the control of food intake. *J Biol Chem* 2004. 279:12005-12008.

14. **Kim EK, Song MJ, Yoo EJ, Choe SS, Park SD, Kim JB.** Regulatory role of glycogen synthase kinase 3 for transcriptional activity of ADD1/SREBP1c. *J Biol Chem* 2004. 279:19970-19975.

15. **Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG.** Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. *J Biol Chem* 1996. 271:27879-27887.

16. **Hamilton SR, O'Donnell JB, Hammet A, Stapleton D, Habinowski SA, Means AR, Kemp BE, Witters LA.** AMP-activated protein kinase kinase: detection with recombinant AMPK alpha1 subunit. *Biochem Biophys Res Commun* 2002. 293:892-898.

17. **Woods A, Vertommen D, Neumann D, Turk R, Bayliss J, Schlattner U, Wallimann T, Carling D, Rider MH.** Identification of phosphorylation sites in AMP-activated protein kinase (AMPK) for upstream AMPK kinases and study of their roles by site-directed mutagenesis. *J Biol Chem* 2003. 278:28434-28442.

18. **Hawley SA, Boudau J, Reid JL, Mustard JK, Udd L, Makela TP, Alessi DR, Hardie DG.** Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *J Biol* 2003. 2:28.

19. **Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN.** The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. *Cancer Prev Res (Phila)* 2008. 1:369-375.

20. **Hawley SA, Selbert MA, Goldstein EG, Edelman AM, Carling D, Hardie DG.** 5'-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. *J Biol Chem* 1995. 270(45):27186-27191.

21. **Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, De Pinho RA, Cantley LC.** The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc Natl Acad Sci USA* 2004. 101:3329-3335.

22. **Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D.** LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Curr Biol* 2003. 13:2004-2008.

23. **Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, Hedrick S, Xu W, Boussouar F, Brindle P, Takemori H, Montminy M.** The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. *Nature* 2005. 437:1109-1111.

24. **Pollak M.** Insulin-like growth factor-related signaling and cancer development. *Recent Results Cancer Res* 2007. 174:49-53.

25. **Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, et al.** LKB1 modulates lung cancer differentiation and metastasis. *Nature* 2007. 448:807-810.

26. **Shaw RJ, Katja A, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC.** The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin. *Science* 2005. 310(5754):1642-1646.

27. **Mu J, Brozinick JT, Valladares O, Bucan M, Birnbaum MJ.** A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. *Mol Cell* 2001. 7:1085-1094.

28. **Fryer LG, Parbu-Patel A, Carling D.** The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. *J Biol Chem* 2002. 277:25226-25232.

29. **Hezel AF, Bardeesy N.** LKB1; linking cell structure and tumor suppression. *Oncogene* 2008. 27:6908-6919.

30. **Shackelford DB, Shaw RJ.** The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. *Nat Rev Cancer* 2009. 9:563-575.

31. **Liu B, Fan Z, Edgerton SM, Denq XS, Alimova IN, Lind SE, Thor AD.** Metformin induces unique biological and molecular responses in triple negative breast cancer cells. *Cell Cycle* 2009. 8:2031-2040.

32. **Inoki K, Zhu T, Guan KL.** TSC2 mediates cellular energy response to control cell growth and survival. *Cell* 2003. 115:577-590.

33. **Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ.** AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol Cell* 2008. 30:214-226.

34. **Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB.** Sys-

temic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. *Cancer Res* 2007. 67:6745-6752.

35. **Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M.** Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. *Endocr Relat Cancer* 2010. 17:351-360.

36. **Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K.** Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. *Cancer Res* 2009. 69:7507-7511.

37. **Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, Nakajima A.** Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. *Mol Carcinog* 2010. 49:662-671.

38. **Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama H, Nakajima A.** Metformin suppresses intestinal polyp growth in ApcMin/+ mice. *Cancer Sci* 2008. 99:2136-2141.

39. **Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M.** Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. *Endocr Relat Cancer* 2010. 17:351-360.

40. **Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C Boyer O, Bardet V, Park S, Foretz M, et al.** The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. *Blood* 2010. 116:4262-4273.

41. **Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M, Falcieri E, Bortu R, Melchionda F, Iacobucci I, et al.** AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. *Leukemia* 2012. 26:91-100.

42. **Ben Sahra BI, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F.** The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. *Oncogene* 2008. 27:3576-3586.

43. **Gou S, Cui P, Li X, Shi P, Liu T, Wang C.** Low concentrations of metformin selectively inhibited CD133+ cell proliferation in pancreatic cancer and have anti-cancer action. *Plos One* 2013. 8(5):e63969.

44. **Song CW, Lee H, Dings RPM, Williams B, Powers J, Santos TD, Choi BH, Park HJ.** Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. *Scientific Reports* 2012. 362.

45. **Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I.** In vitro metformin antineoplastic activity in epithelial ovarian cancer. *Gynecol Oncol* 2008. 110:246-250.

46. **Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M.** Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. *Cancer Res* 2006. 66:10269-10273.

47. **Zhuang Y, Miskimins WK.** Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. *J Mol Signal* 2008. 3:18.

48. **Schneider MB, Matsuzaki H, Haorah J, Shiomori K, Ogawa M.** Prevention of pancreatic cancer induction in hamsters by metformin. *Gastroenterology* 2001. 120:1263-1270.

49. **Hay N.** The Akt-mTOR tango and its relevance to cancer. *Cancer Cell* 2005. 8:179-83.

50. **Bhaskar PT, Hay N.** The two TORCs and Akt. *Dev Cell* 2007. 12:487-502.

51. **Hardie DG.** AMPK and Raptor: matching cell growth to energy supply. *Mol Cell* 2008. 30:263-265.

52. **Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N.** Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. *J Biol Chem* 2005. 280:32081-32089.

53. **Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR.** Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. *J Biol Chem* 2003. 278:39422-39427.

54. **Longo R, D'Andrea MR, Sarmiento R, Salerno F, Gasparini G.** Integrated therapy of kidney cancer. *Ann Oncol* 2007. 18:141-148.

55. **Hager M, Haufe H, Kemmerling R, Hitzl W, Mikuz G, Moser PL, Kolbitsch C.** Increased activated Akt expression in renal cell carcinomas and prognosis. *J Cell Mol Med* 2009. 13:2181-2188.

56. **Cho D, Signoretti S, Regan M, Mier JW, Atkins MB.** The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. *Clin Cancer Res* 2007. 13:758-763.

57. **Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, et al.** Temsirolimus, interferon-alpha or both for advanced renal-cell carcinoma. *N Engl J Med* 2007. 356:2271-2281.

58. **Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC.** Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. *Mol Cell* 2009. 33:237-247.

59. **Woodard J, Platanias LC.** AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. *Biochem Biophys Res Commun* 2010. 398(1):135-139.

60. **Grenader T, Goldberg A, Shavit L.** Metformin as an addition to conventional chemotherapy in breast cancer. *J Clin Oncol* 2009. 35:e259; author reply e260.

61. **Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J.** Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. *Breast Cancer Res Treat* 2013. 137(3):807-816.

62. **Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A.** Is it time to test metformin in breast cancer clinical trials? *Cancer Epidemiol Biomarkers Prev* 2009. 18(3):701-705.

63. **Lewis JD, Capra AM, Achacoso NS.** Medical therapy for diabetes is associated with increased use of lower endoscopy. *Pharmacoepidemiol Drug Saf* 2007. 16:1195-1202.

64. **Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH.** The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. *Int J Cancer* 2012. 131(3):752-759.

65. **Lee JH, Jeon SM, Hong SP, Cheon JH, Kim TI, Kim**

WH. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. *Dig Liver Dis* 2012. 44(12):1042-1047.

66. **Spillane S, Bennett K, Sharp L, Barron T.** A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2013. 22(8):1364-1373.

67. **Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, Kip KE.** Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. *Diabetes Care* 2011. 34(10):2323-2328.

68. **Currie CJ, Poole CD, Gale EA.** The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. *Diabetologia* 2009. 52:1766-1777.

69. **Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD.** Metformin and reduced risk of cancer in diabetic patients. *BMJ* 2005. 330:1304-1305.

70. **Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH.** Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. *Diabetes Care* 2012. 35:119-124.

71. **Monami M, Colombi C, Balzi D, Dicembrini I, Giannini S, Melani C, Vitale V, Romano D, Barchielli A, Marchionni N, Rotella CM, Mannucci E.** Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. *Diabetes Care* 2011. 34(1):129-131.

72. **Geraldine N, Marc A, Carla T, Chantal M, Stefaan B, Welcome W, Frank B.** Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting. *Diabetes Res Clin Pract* 2012. 97:331-336.

73. **Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC.** Anti-diabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. *Clin Lung Cancer* 2012. 13:143-148.

74. **Wright JL, Stanford JL.** Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. *Cancer Causes Control* 2009. 20:1617-1622.

75. **Donadon V, Balbi M, Mas MD, Casarin P, Zanette G.** Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. *Liver Int* 2010. 30:750-758.

76. **Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN.** Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. *Cancer* 2010. 116:1938-1946.

77. **Bodmer M, Meier C, Krähenbuhl S, Jick SS, Meier CR.** Long-term metformin use is associated with decreased risk of breast cancer. *Diabetes Care* 2010. 33:1304-1308.

78. **Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL.** Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. *Cancer Epidemiol Biomarkers Prev* 2011. 20:101-111.

79. **Bodmer M, Becker C, Meier C, Jick SS, Meier CR.** Use of metformin and the risk of ovarian cancer: a case-control analysis. *Gynecol Oncol* 2011. 123:200-204.

80. **Bodmer M, Becker C, Meier C, Jick SS, Meier CR.** Use of anti-diabetic agents and the risk of pancreatic cancer:

a case control analysis. *Am J Gastroenterol* 2012. 107:620-626.

81. **Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM.** New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. *Diabetes Care* 2009. 32:1620-1625.

82. **Hernandez-Dıaz S, Adami HO.** Diabetes therapy and cancer risk: causal effects and other plausible explanations. *Diabetologia* 2010. 53:802-808.

83. **Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL.** Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. *Diabetes Care* 2012. 35:299-304.

84. **Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ.** Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. *Diabetes Care* 2010. 33(2):322-326.

85. **He XX, Tu SM, Lee MH, Yeung SC.** Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. *Ann Oncol* 2011. 22:2640-2645.

86. **Yang YX.** Do diabetes drugs modify the risk of pancreatic cancer? *Gastroenterology* 2009. 137:412-415.

87. **Rizos CV, Elisaf MS.** Metformin and cancer. *Eur J Pharmacol* 2013. 705(1-3):96-108.

88. **Suissa S, Azoulay L.** Metformin and the risk of cancer: time-related biases in observational studies. *Diabetes Care* 2012. 35(12):2665-2673.

89. **Goodwin PJ, Ligibel JA, Stambolic V.** Metformin in breast cancer: time for action. *J Clin Oncol* 2009. 27:3271-3273.

90. **Sandhu MS, Dunger DB, Giovannucci EL.** Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. *J Natl Cancer Inst* 2002. 94:972-980.

91. **LeRoith D, Baserga R, Helman L, Roberts CT Jr.** Insulin-like growth factors and cancer. *Ann Intern Med* 1995. 122:54-59.

92. **Pollak M.** Insulin and insulin-like growth factor signalling in neoplasia. *Nat Rev Cancer* 2008. 8:915-928.

93. **Denley A, Carroll JM, Brierley GV, Cosgrove L, Wallace J, Forbes B, Roberts CT Jr.** Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. *Mol Cell Biol* 2007. 27:3569-3577.

94. **Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M.** Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* 2008. 371:569-578.

95. **van Kruijsdijk RC, van der Wall E, Visseren FL.** Obesity and cancer: the role of dysfunctional adipose tissue. *Cancer Epidemiol Biomarkers Prev* 2009. 18:2569-2578.

96. **Ulisse S, Baldini E, Sorrenti S, D'Armiento M.** The urokinase plasminogen activator system: a target for anticancer therapy. *Curr Cancer Drug Targets* 2009. 9:32-71.

97. **Yu H, Pardoll D, Jove R.** STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer* 2009. 9:798-809.

98. **Zhuang Y, Miskimins WK.** Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. *J Mol Signal* 2008. 3:18.